Valuation Charles River Laboratories International, Inc. Berne S.E.

Stocks

End-of-day quote Berne S.E. 16/09/2026			5-day change	1st Jan Change
226.97 ^CHF	+2.07%		+0.87%	-

05:24pm	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
04:25pm	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	13,052	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	30.22%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	15,165	14,683	14,289
Change	-	-36.28%	7.39%	-20.91%	3.29%	26.94%	-3.18%	-2.68%
P/E	49.4x	23.1x	25.9x	931x	-70x	73.1x	31.4x	26.2x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	4.33x	3.68x	3.27x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	1.3x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	3.34x	3.26x	3.1x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	3.88x	3.67x	3.4x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	15x	13.4x	12.1x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	18.5x	16.1x	14.3x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	48x	24.1x	29.9x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	2.08%	4.15%	3.34%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	3.738	8.718	10.43
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,911	4,001	4,208
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,008	1,095	1,180
EBIT ¹	742.1	834	838.8	805.9	793.9	821	912.3	1,001
Net income ¹	391	486.2	474.6	10.3	-144.3	162.4	427.7	471.2
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,112	1,631	1,237
Reference price ²	375.34	218.92	238.84	186.16	203.66	273.41	273.41	273.41
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	16/02/22	22/02/23	14/02/24	19/02/25	18/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
LONZA GROUP AG	31.46x	5.67x	16.98x	1.03%	45.91B
IQVIA HOLDINGS INC.	34.62x	3.34x	14.39x	-.--%	44.25B
REVOLUTION MEDICINES, INC.	-20.04x	230.9x	-21.44x	-.--%	41.99B
BEONE MEDICINES AG	45.6x	5.26x	28.79x	-.--%	39.58B
CELLTRION, INC.	26.88x	8.11x	20.55x	0.42%	31.08B
MEDPACE HOLDINGS, INC.	35.05x	5.75x	26.13x	-.--%	17.21B
EUROFINS SCIENTIFIC SE	24.9x	2.15x	9.33x	1.07%	14.96B
ICON PUBLIC LIMITED COMPANY	29.53x	1.94x	11.89x	-.--%	13.42B
Average	26.00x	32.89x	13.33x	0.32%	31.05B
Weighted average by Cap.	24.75x	43.16x	12.25x	0.31%